Cohort C: bevacizumab — Competitive Intelligence Brief

Cohort C: bevacizumab (Cohort C: bevacizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiogenesis inhibitor. Area: Oncology.

phase 2 Angiogenesis inhibitor VEGF-A Oncology Small molecule

Target snapshot

Cohort C: bevacizumab (Cohort C: bevacizumab) — PPD Development, LP. Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cohort C: bevacizumab TARGET	Cohort C: bevacizumab	PPD Development, LP	phase 2	Angiogenesis inhibitor	VEGF-A
Ketorolac + Ranibizumab	Ketorolac + Ranibizumab	Università degli Studi di Brescia	marketed	NSAID + anti-VEGF monoclonal antibody fragment	COX enzymes (ketorolac); VEGF-A (ranibizumab)
Aflibercept Injection [Eylea]	Aflibercept Injection [Eylea]	Caregen Co. Ltd.	marketed	VEGF inhibitor (soluble decoy receptor)	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Anti-VEGF drug	Anti-VEGF drug	Xiaodong Sun	marketed	Anti-VEGF	VEGF-A
Intravitreal Ranibizumabe	Intravitreal Ranibizumabe	University of Sao Paulo	marketed	VEGF-A inhibitor; monoclonal antibody fragment	VEGF-A (Vascular Endothelial Growth Factor A)
intra-vitreal injection of Ranibizumab	intra-vitreal injection of Ranibizumab	Ain Shams University	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Intravitreal ranibizumab	Intravitreal ranibizumab	LEANDRO CABRAL ZACHARIAS	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiogenesis inhibitor class)

1. Jiangsu Simcere Pharmaceutical Co., Ltd. · 3 drugs in this class
2. Eli Lilly and Company · 1 drug in this class
3. Guangzhou Institute of Respiratory Disease · 1 drug in this class
4. Hoffmann-La Roche · 1 drug in this class
5. Liaoning Cancer Hospital & Institute · 1 drug in this class
6. PPD Development, LP · 1 drug in this class
7. Peking University Cancer Hospital & Institute · 1 drug in this class
8. Sanofi · 1 drug in this class
9. ARCAGY/ GINECO GROUP · 1 drug in this class
10. Second Affiliated Hospital of Xi'an Jiaotong University · 1 drug in this class